Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

Novel compound for targeted tumor therapy in patients with soft tissue sarcoma

Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001

04-Apr-2023 - Thermosome announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023. The primary ...

Indivumed and CELLphenomics Announce Partnership for Improved Cancer Patient Care

European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types

12-Sep-2022 - Indivumed GmbH and CELLphenomics GmbH announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to ...

Evotec launches “PRROTECT”, a pre-competitive initiative to be better prepared for future pandemics

16-Jun-2021 - Evotec SE announced that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future. Virus outbreaks that can develop into ...

Merck and Artios will conduct collaborative research

Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

03-Dec-2020 - Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...

Merck Aims to Return to Profitable Growth as of 2019

Performance Materials realigns R&D

16-Oct-2018 - Merck expects strong growth impetus starting next year, as the company reported to analysts and investors at its Capital Markets Day. “2018 has been a challenging year for Merck. We have made future-oriented decisions that will lead to profitable growth as of next year,” said Stefan Oschmann, ...

Merck Invests in its Biotech Manufacturing Site in Bari

New production line for the aseptic filling of biotech medicines under isolator

04-Oct-2017 - Merck will invest €35 million in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari, Italy. The announcement was made as part of an event celebrating the 25th anniversary of the site and its leading role on the science and ...

Merck Generates Record Sales

09-Mar-2017 - Merck finished 2016 with record figures and continued to grow profitably. Sales and earnings rose significantly. Major strategic advances were made in all three business sectors. “2016 was a successful year for Merck. In Healthcare, two of our compounds are in registration. In our Life Science ...

Merck Serono to Collaborate With The Institute of Cancer Research, London, and Wellcome Trust

Joint program to develop drug candidates for the treatment of different forms of cancer

08-Oct-2014 - Merck Serono, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an ...

Evotec receives first milestone in Roche biomarker collaboration

25-Apr-2014 - Evotec AG announced the successful achievement of a milestone in its biomarker alliance with Roche. The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended phase I oncology trial. This is the ...